Explore ViiV Healthcare

Medicines in Development

ViiV Healthcare is committed to developing new medicines for HIV to reduce its impact on the more than 36 million people living with the virus.1 Our scientists and researchers continue to work to identify new ways to lessen the burden not only of the disease, but also of daily treatment of HIV.

Clinical development pipeline 

Product Class Phase 

dolutegravir + lamivudine

INSTI + NRTI

III 

LA cabotegravir + LA rilpivirine*

(for intramuscular injection)
INSTI + NNRTI

III

LA cabotegravir

INSTI

III

fostemsavir

Attachment inhibitor

III

Combinectin (GSK3732394)

Entry inhibitor

Pre-clinical 

GSK3640254

Maturation inhibitor

Pre-clinical

*in collaboration with Janssen

INSTI = integrase strand transfer inhibitor; LA = long-acting; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside transcriptase inhibitor; STR = single-tablet regimen

1. UNAIDS. Global HIV & AIDS Statistics — 2018 Fact Sheet. Available at: http://www.unaids.org/en/resources/fact-sheet. Last Accessed October 2018.

Website images are not intended to imply that the models pictured have HIV.